AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28222073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rucaparib (240 mg per day) combined with carboplatin (AUC 5 mg/ml)
Number of subjects: 85
Study 28222073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rucaparib combined with various chemotherapy regimens (carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, epirubicin/cyclophosphamide)
Number of subjects: 85
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PGL-I serology
Number of subjects: 452
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LID-1 serology
Number of subjects: 452
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ND-O-LID serology
Number of subjects: 452
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacilloscopic index (BI) categories
Number of subjects: 452
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: BI categories (0<BI<3)
Number of subjects: 452
Study 28222139 — intervention group
Group type: EXPERIMENTAL
Intervention: BI≥3
Number of subjects: 452
Study 28222249 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase to platelet ratio index
Number of subjects: 582
Study 28222249 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 582
Study 28222249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-glutamyl transpeptidase to platelet ratio
Number of subjects: 582
Study 28222707 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool (SBT)
Number of subjects: 329
Study 28222707 — intervention group
Group type: COMPARATOR
Intervention: Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ-short)
Number of subjects: 329
Study 28222707 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT and ÖMPSQ-short classification to high or low risk for long-term pain and disability
Number of subjects: 329
Study 28222707 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT in clinical practice
Number of subjects: 329
Study 28223036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 24
Study 28223036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 24
Study 28223036 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 28223062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 37
Study 28223297 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 8
Study 28223428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Flex Embolization Device with Shield Technology (PFLEX)
Number of subjects: 50
Study 28223466 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 24
Study 28224463 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0
Study 28225505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/d
Number of subjects: 1
Study 28225505 — intervention group
Group type: COMPARATOR
Intervention: Conventional optimal medical therapy
Number of subjects: 1
Study 28225683 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Chlamydia trachomatis infections
Number of subjects: 0
Study 28226027 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest vitamin D levels
Number of subjects: 63
Study 28226027 — intervention group
Group type: COMPARATOR
Intervention: Lowest vitamin D levels
Number of subjects: 63
Study 28226027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 63
Study 28228115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss of 10% combined with exercise
Number of subjects: 820
Study 28228115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss and exercise intervention
Number of subjects: 820
Study 28228115 — intervention group
Group type: EXPERIMENTAL
Intervention: Community program for diet-induced weight loss and exercise
Number of subjects: 820
Study 28228116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention year 1 cohort
Number of subjects: 1233
Study 28228116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention year 2 cohort
Number of subjects: 1233
Study 28228116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention year 1 and year 2 cohorts
Number of subjects: 1233
Study 28228123 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group (EG)
Number of subjects: 0
Study 28228123 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 28228318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood of offspring from mothers with PCOS
Number of subjects: 143
Study 28228318 — intervention group
Group type: COMPARATOR
Intervention: Cord blood of healthy controls
Number of subjects: 143
Study 28228332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 27
Study 28228332 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Number of subjects: 27
Study 28228332 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Phase (no food provision and no in-person contact)
Number of subjects: 27
Study 28228369 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative wound monitoring using smartphone digital images
Number of subjects: 40
Study 28228422 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of palatable food
Number of subjects: 0
Study 28228453 — intervention group
Group type: EXPERIMENTAL
Intervention: NOCAD patients
Number of subjects: 523
Study 28228453 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with NOCAD
Number of subjects: 523
Study 28228453 — intervention group
Group type: COMPARATOR
Intervention: Men and women with NOCAD
Number of subjects: 523
Study 28228453 — intervention group
Group type: COMPARATOR
Intervention: General population (reference group)
Number of subjects: 523
Study 28228461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) measured 1 month after AMI
Number of subjects: 2219
Study 28228461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein-associated phospholipase A2 measured 1 month after AMI
Number of subjects: 2219
Study 28228461 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP levels and health status at 12 months
Number of subjects: 2219
Study 28228461 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual inflammatory risk (hsCRP >3 mg/L)
Number of subjects: 2219
Study 28228508 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk iodine concentration
Number of subjects: 0
Study 28228508 — intervention group
Group type: COMPARATOR
Intervention: Urinary iodine concentration
Number of subjects: 0
Study 28228848 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Brazilian meal pattern (white rice, beans, beer, processed and fresh meats)
Number of subjects: 10010
Study 28228848 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Brazilian fast foods/full fat dairy/milk based desserts pattern
Number of subjects: 10010
Study 28228848 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH Diet pattern
Number of subjects: 10010
Study 28228848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, light foods and beverages/low fat dairy pattern
Number of subjects: 10010
Study 28228848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables/fruit dietary pattern
Number of subjects: 10010
Study 28228938 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week in-hospital exercise training programme
Number of subjects: 39
Study 28228938 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 39
Study 28229126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous solanezumab
Number of subjects: 1322
Study 28229126 — intervention group
Group type: COMPARATOR
Intervention: Caregiver assessment
Number of subjects: 1322
Study 28229126 — intervention group
Group type: COMPARATOR
Intervention: Clinical/health measures
Number of subjects: 1322
Study 28229893 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg intravenous
Number of subjects: 161
Study 28229893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 28230575 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study with semistructured interviews
Number of subjects: 22
Study 28230704 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) group
Number of subjects: 31
Study 28230704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 28230704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during handgrip exercise
Number of subjects: 31
Study 28230704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during PHMI
Number of subjects: 31
Study 28230704 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MSNA due to PHMI
Number of subjects: 31
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 66
Study 28231027 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia and poor sleep quality
Number of subjects: 66
Study 28231247 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 66
Study 28231622 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized aggressive periodontitis (LAgP)
Number of subjects: 160
Study 28231622 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized aggressive periodontitis (GAgP)
Number of subjects: 160
Study 28231622 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (H)
Number of subjects: 160
Study 28231791 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered Thinking Healthy Programme for perinatal depression, delivered over six months by trained peers.
Number of subjects: 44
Study 28231807 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measures of adiposity (DXA-derived)
Number of subjects: 288
Study 28231807 — intervention group
Group type: COMPARATOR
Intervention: Indirect measures of adiposity
Number of subjects: 288
Study 28231807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of direct and indirect measures of adiposity
Number of subjects: 288
Study 28231814 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMS
Number of subjects: 1068
Study 28231814 — intervention group
Group type: COMPARATOR
Intervention: GEMS
Number of subjects: 1068
Study 28231834 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5-, IL-17A-/F- and IL-25- high profile (Cluster 1, n=24)
Number of subjects: 205
Study 28231834 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5-high or IL-10-high (Cluster 2, n=16)
Number of subjects: 205
Study 28231834 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6-high (Cluster 3, n=8)
Number of subjects: 205
Study 28231834 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-22-high (Cluster 4, n=25)
Number of subjects: 205
Study 28231834 — intervention group
Group type: EXPERIMENTAL
Intervention: No cytokine-high pattern or only high IL-4 and/or IL-13 (Cluster 5, n=132)
Number of subjects: 205
Study 28231838 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous measurement of maximum diameter using cardiovascular magnetic resonance (CMR) scans
Number of subjects: 15
Study 28231838 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous measurement of maximum diameter using CMR
Number of subjects: 15
Study 28231942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin
Number of subjects: 17717
Study 28231942 — intervention group
Group type: COMPARATOR
Intervention: Placebo and simvastatin
Number of subjects: 17717
Study 28233565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 660
Study 28233565 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 660
Study 28233591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-sparing radiotherapy
Number of subjects: 135
Study 28235011 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-originated trials (N = 9 trials)
Number of subjects: 50
Study 28235011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had not completed high school
Number of subjects: 50
Study 28235011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient understanding
Number of subjects: 50
Study 28235011 — intervention group
Group type: COMPARATOR
Intervention: Type of cancer therapy
Number of subjects: 50
Study 28235011 — intervention group
Group type: COMPARATOR
Intervention: Trial sponsor
Number of subjects: 50
Study 28235771 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with histamine dihydrochloride (HDC) and low-dose IL-2
Number of subjects: 84
Study 28235835 — intervention group
Group type: EXPERIMENTAL
Intervention: Most educated mothers (22% exclusively breastfed)
Number of subjects: 1598
Study 28235835 — intervention group
Group type: COMPARATOR
Intervention: Least educated mothers (7% exclusively breastfed)
Number of subjects: 1598
Study 28235835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for sociodemographic factors, smoking habits, and breastfeeding difficulties
Number of subjects: 1598
Study 28235848 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT2 patients underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling.
Number of subjects: 33
Study 28235848 — intervention group
Group type: COMPARATOR
Intervention: Control participants underwent the same 6-hour 75-g oral glucose tolerance test.
Number of subjects: 33
Study 28235848 — intervention group
Group type: EXPERIMENTAL
Intervention: LQT2 patients during glucose ingestion.
Number of subjects: 33
Study 28235964 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of moderate physical activity per school day (intervention group)
Number of subjects: 1339
Study 28235964 — intervention group
Group type: COMPARATOR
Intervention: 60 minutes of physical activity per week (control group)
Number of subjects: 1339
Study 28236024 — intervention group
Group type: EXPERIMENTAL
Intervention: PulmoBind SPECT imaging
Number of subjects: 30
Study 28236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50mg/day
Number of subjects: 0
Study 28236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100mg/day
Number of subjects: 0
Study 28236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 200mg/day
Number of subjects: 0
Study 28236727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28237286 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score (refined form excluding 'labile INR')
Number of subjects: 4579
Study 28237286 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BED score
Number of subjects: 4579
Study 28237286 — intervention group
Group type: COMPARATOR
Intervention: CHADS score
Number of subjects: 4579
Study 28237791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4032
Study 28237791 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 4032
Study 28237791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in prediabetes subgroup)
Number of subjects: 4032
Study 28237791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in screen-detected diabetes subgroup)
Number of subjects: 4032
Study 28237791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in established diabetes subgroup)
Number of subjects: 4032
Study 28237791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (in normoglycaemia subgroup)
Number of subjects: 4032
Study 28238111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 6
Study 28238467 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient intake assessment
Number of subjects: 904
Study 28238482 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction in girls
Number of subjects: 160
Study 28238482 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction in boys
Number of subjects: 160
Study 28238482 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-SDS reduction
Number of subjects: 160
Study 28238482 — intervention group
Group type: EXPERIMENTAL
Intervention: LH concentration and LH/FSH ratio
Number of subjects: 160
Study 28238482 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment, IGF-1, and IGF-1/IGFBP-3 ratio
Number of subjects: 160
Study 28238483 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 127
Study 28238483 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity
Number of subjects: 127
Study 28238563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0
Study 28238563 — intervention group
Group type: EXPERIMENTAL
Intervention: CA4P plus bevacizumab
Number of subjects: 0
Study 28238563 — intervention group
Group type: COMPARATOR
Intervention: CA4P plus pazopanib
Number of subjects: 0
Study 28238563 — intervention group
Group type: COMPARATOR
Intervention: CA4P plus bevacizumab and chemotherapy
Number of subjects: 0
Study 28238593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients received letrozole (2·5 mg per day orally) or tamoxifen (20 mg per day orally).
Number of subjects: 151
Study 28238593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab in patients with HER2-enriched subtype.
Number of subjects: 151
Study 28238593 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab in patients with non-HER2-enriched subtypes.
Number of subjects: 151
Study 28238593 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype identification.
Number of subjects: 151
Study 28238631 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of QHPV
Number of subjects: 126
Study 28238631 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 doses of QHPV
Number of subjects: 126
Study 28238631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28238701 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate
Number of subjects: 16
Study 28239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary abdominal closure systems (commercial negative pressure)
Number of subjects: 402
Study 28239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial negative pressure temporary closure
Number of subjects: 402
Study 28239409 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin closure and Bogotá bag
Number of subjects: 402
Study 28239472 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, a human IgG1 anti-PD-L1 monoclonal antibody, administered multiple times (exact dosage and duration not specified)
Number of subjects: 123
Study 28239472 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 123
Study 28239485 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling approach (DST)
Number of subjects: 0
Study 28239491 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% fixed-dose combination
Number of subjects: 0
Study 28239491 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker monotherapy
Number of subjects: 0
Study 28240822 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Sfrp3 treatment in myotubes from lean insulin-sensitive subjects
Number of subjects: 41
Study 28240822 — intervention group
Group type: COMPARATOR
Intervention: LPS or recombinant IL-6 treatment in in vitro-differentiated myotubes
Number of subjects: 41
Study 28240822 — intervention group
Group type: COMPARATOR
Intervention: Skeletal muscle (SkM) Sfrp3 mRNA levels
Number of subjects: 41
Study 28240822 — intervention group
Group type: COMPARATOR
Intervention: Serum Sfrp3 levels
Number of subjects: 41
Study 28240822 — intervention group
Group type: COMPARATOR
Intervention: Correlation of SkM Sfrp3 mRNA levels
Number of subjects: 41
Study 28241770 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of tobacco use treatment guidelines using the Consolidated Framework for Implementation Research (CFIR)
Number of subjects: 40
Study 28241770 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with CHC medical directors, health care providers, and village health workers
Number of subjects: 40
Study 28241807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose external beam radiation therapy (RT)
Number of subjects: 756
Study 28241824 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) injections and topical application of PRP gel
Number of subjects: 24
Study 28241824 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) injections
Number of subjects: 24
Study 28241844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 28242046 — intervention group
Group type: EXPERIMENTAL
Intervention: mtDNA content in peripheral blood cells (PBCs)
Number of subjects: 400
Study 28243404 — intervention group
Group type: EXPERIMENTAL
Intervention: Persumac (prepared from Rhus Coriaria and Bunium Persicum Boiss)
Number of subjects: 93
Study 28243404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 93
Study 28243404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antiemetic therapy for CINV
Number of subjects: 93
Study 28243468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 672
Study 28243577 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase treatment
Number of subjects: 26
Study 28243592 — intervention group
Group type: EXPERIMENTAL
Intervention: HD Mesh Ablator
Number of subjects: 0